Opendata, web and dolomites

SCilS SIGNED

Studying Ciliary Signaling in Development and Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SCilS project word cloud

Explore the words cloud of the SCilS project. It provides you a very rough idea of what is the project "SCilS" about.

gt    etiology    designed    400    stem    thereby    surface    cell    scils    cilia    cryo    microtubule    unavailable    disease    individual    stage    genomics    academia    degree    feedback    competences    network    models    signalling    tissues    accomplished    projections    public    genetic    electron    biology    ciliopathy    dysfunctional    concentrate    segregate    robustness    heterogeneous    sectors    create    training    industry    sessions    zebrafish    multidisciplinary    traits    tomography    critical    understand    output    cutting    of    structural    human    intersectoral    esrs    proteomics    career    components    severe    cellular    phenotypes    signaling    prospects    overlapping    integrating    secondments    give    cells    super    outstanding    mediated    regulation    bioinformatics    resolution    expertise    private    academic    ciliary    unparalleled    organization    biochemistry    efficient    people    industrial    esr    35    majority    hubs    uncover    attractive    homeostasis    imaging    organs    edge    therapeutic    primary    organoid    interventions    ciliopathies    settings    broad   

Project "SCilS" data sheet

The following table provides information about the project.

Coordinator
STICHTING KATHOLIEKE UNIVERSITEIT 

Organization address
address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ
website: www.radboudumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 3˙844˙874 €
 EC max contribution 3˙844˙874 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) coordinator 531˙239.00
2    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) participant 892˙566.00
3    IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES FONDATION FR (PARIS 15) participant 549˙604.00
4    NEWCELLS BIOTECH LIMITED UK (NEWCASTLE UPON TYNE) participant 303˙172.00
5    AARHUS UNIVERSITET DK (AARHUS C) participant 297˙522.00
6    OSPEDALE SAN RAFFAELE SRL IT (MILANO) participant 261˙499.00
7    CELL NETWORKS GMBH DE (HEIDELBERG) participant 252˙788.00
8    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 252˙788.00
9    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) participant 252˙788.00
10    ZECLINICS SL ES (BARCELONA) participant 250˙904.00

Map

 Project objective

SCilS will create a multidisciplinary and intersectoral European training network focusing on ciliary signalling in development and disease. Primary cilia are microtubule-based cell surface projections that have evolved to be key signalling hubs of our cells, as they concentrate or segregate components of major cellular signalling pathways. Control of ciliary signaling output requires a high degree of regulation and critical feedback, which is needed for robustness in development and cellular homeostasis of different tissues and organs. Dysfunctional cilia can therefore lead to >35 severe human genetic traits (ciliopathies) with highly heterogeneous, overlapping phenotypes. Ciliopathies affect as many as 1 in 400 people, and for the majority of cases efficient therapeutic interventions are currently unavailable. SCilS research aims to uncover the multi-level organization and regulation of cilia-mediated signalling pathways in order to understand ciliopathy disease etiology and identify novel therapeutic targets. This challenging task will be accomplished by integrating unique expertise and cutting edge technology available within the SCilS network, including structural biology, super resolution imaging and cryo-electron tomography, state-of-the-art genomics, proteomics and bioinformatics, (stem) cell biology and biochemistry, as well as organoid technology and zebrafish models. SCilS training will give Early Stage Researchers (ESRs) unparalleled training opportunities in outstanding academic and industrial settings through training-by-research via individual research projects, secondments, and network-wide training sessions. All individual training and research activities have been designed to provide each ESR with the necessary broad competences in state‐of‐the art academic and industrial research. The network will thereby make a career in both industry and academia attractive to the ESRs and improve their career prospects in both private and public sectors.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SCILS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SCILS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

SAMCAPS (2018)

Self-Assembled MicroCAPSules: Synthesis, Characterization, and Eco-friendly Application in Home Care Products

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More